Actively Recruiting
Study on the Safety and Efficacy of MR-Linac Technique in Patients With Unresectable Locally Advanced Colon Cancer
Led by Sichuan Cancer Hospital and Research Institute · Updated on 2025-09-09
20
Participants Needed
1
Research Sites
195 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In this phase I single-arm clinical study, 20 patients with T4 unresectable locally advanced colon cancer are proposed to be enrolled, who will be treated with MR-Linac with short course radiotherapy (25Gy/5F), followed by 4 cycles of mFOLFOX6 or 3 cycles of XELOX chemotherapy, then radical surgical resection, and then postoperatively with 8 cycles of mFOLFOX6 or 5 cycles of XELOX. The study will assess patients' surgical R0 resection rate, pCR or cCR rate, PFS, OS, and related adverse effects of treatment, aiming to explore the feasibility, safety, and efficacy of MR-Linac in the treatment of unresectable locally advanced colon cancer.
CONDITIONS
Official Title
Study on the Safety and Efficacy of MR-Linac Technique in Patients With Unresectable Locally Advanced Colon Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients over 18 years old
- Able to remain still on the treatment bed for 1 to 1.5 hours
- ECOG performance status score of 0 or 1
- Diagnosed with colon adenocarcinoma at clinical stage cT4N0-2M0
- Normal organ function with specified blood counts and liver/kidney function levels
- Able to follow the study protocol during the research
- Signed written informed consent
You will not qualify if you...
- Deficient mismatch repair (dMMR) or high microsatellite instability (MSI-H)
- Presence of other tumors besides colon adenocarcinoma
- Claustrophobia or inability to undergo MRI due to metal implants or other reasons
- Presence of distant metastasis (M1)
- Pregnant or lactating women
- Previous anti-tumor treatment
- Use of prohibited drugs during treatment
- Known HIV infection or acquired immunodeficiency syndrome
- Significant active cardiovascular diseases within 6 months prior to enrollment
- Uncontrolled epilepsy, central nervous system disorders, or mental illness affecting consent or compliance
- Organ transplant requiring immunosuppressive therapy
- Severe uncontrolled infections or other serious comorbid conditions
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sichuan Cancer Hospital & Institute, Affiliated Cancer Hospital of University of Electronic Science and Technology of China.
Chengdu, Sichuan, China, 610042
Actively Recruiting
Research Team
Q
Qian - Peng, chief physician
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here